Glaxosmithkline And Seroxat
EDM number 2172 in 2005-06, proposed by Paul Flynn on 15/05/2006.
That this House condemns GlaxoSmithKline (GSK) for concealing for 15 years evidence that their anti-depressant drug Seroxat increases the risk of suicide and leads to `persistently worse' depression; congratulates the US Food and Drug Administration for forcing GSK to confess that users of Seroxat `experience emergent suicidality or symptoms that might be precursors to worsening depression or suicidality' and that `these symptoms may be severe and abrupt in onset'; and regrets the likely loss of life that has resulted from repeated denials of the lethal side effects of Seroxat by GSK, the Association of the British Pharmaceutical Industry and the Medicine and Healthcare Product Regulatory Agency in spite of the vigorous campaigns to reveal the truth by Professor David Healy, hon. Members, the Seroxat Users Group and Panorama.
This motion has been signed by a total of 40 MPs.
Download raw data as csv or xml.